Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi

Pfizer (PFE.N) is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates could grow to become the standard of care.